A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)
This study is ongoing, but not recruiting participants.
First Posted: October 16, 2008
Last Update Posted: June 20, 2017
Information provided by (Responsible Party):